Sopan Pharmaceuticals IPO Issue Opens For Migrant Nepalis

13th March 2026, Kathmandu

Sopan Pharmaceuticals Limited is set to launch its Initial Public Offering (IPO) on Chaitra 9, 2082 (March 23, 2026), marking a significant milestone for the company and the Nepali healthcare manufacturing sector.

Sopan Pharmaceuticals IPO Issue

In this first phase, the company is specifically targeting Nepali citizens working abroad under the 10% remittance quota. With a total of 4,290,000 ordinary shares approved for issuance by the Securities Board of Nepal (SEBON) at a par value of 100 rupees per unit, this offering aims to funnel global Nepali capital into domestic pharmaceutical growth.

IPO Allocation and Phase 1 Details

The company has structured its capital raising process to comply with regulatory mandates that favor institutional stability and inclusion for migrant labor. The 4.29 million shares are distributed as follows:

Migrant Workers (Phase 1): 429,000 shares.

Mutual Funds: 214,500 shares.

Company Employees: 171,600 shares.

General Public (Phase 2): 3,474,900 shares.

The first phase is exclusively for Nepalis who have secured official labor approval (Shram Swikriti) and are contributing to the national economy through formal remittance channels.

Key Dates and Application Limits

Investors participating in the first phase must adhere to a strict four-day subscription window:

Opening Date: Chaitra 9, 2082 (March 23, 2026)

Closing Date: Chaitra 12, 2082 (March 26, 2026)

Advertisement

Application parameters have been set to encourage wide participation:

Minimum Application: 10 units (1,000 rupees).

Maximum Application: 11,000 units (1,100,000 rupees).

Eligibility Requirements for Overseas Investors

To successfully apply under the migrant worker quota, applicants must meet specific criteria established by SEBON:

Remittance Account: You must have an ASBA-enabled “Remittance Savings Account” in a Nepali bank.

Remittance Proof: You must have deposited at least 50,000 rupees into this account via formal banking channels within the six months prior to the application.

Labor Permit: A valid work permit issued by the Department of Foreign Employment is mandatory.

C-ASBA & MeroShare: Applicants must have a valid CRN number and access to the MeroShare portal to submit their bid electronically.

Strategic Role of NMB Capital

NMB Capital Limited has been appointed as the Issue and Sales Manager for this IPO. As a leading merchant bank in Nepal, NMB Capital is responsible for the integrity of the bidding process, ensuring that the 429,000 shares for migrant workers are allotted transparently. Following the completion of this phase, they will oversee the much larger public issuance.

The Outlook for Nepali Pharmaceuticals

Sopan Pharmaceuticals is positioning itself as a key player in a sector traditionally dominated by imports. By raising 429 million rupees through this IPO, the company plans to scale its manufacturing capabilities, which currently include a wide range of generic formulations across tablets, liquids, and ointments. For investors, this represents an opportunity to hold equity in a company that is part of an essential industry with high domestic demand and potential for regional export.

As the Chaitra 9 opening date approaches, eligible migrant workers should ensure their remittance accounts are updated and their MeroShare credentials are ready for use.

For More: Sopan Pharmaceuticals IPO Issue